disease 3,759 words KG: ent-dise-7446954b
Contents

Frontotemporal Dementia

Disease Info
Typical OnsetTypically 45-65 years, though ranges from 20-80 years
Behavioral Variant FTD (bvFTD)Characterized by disinhibition, apathy, loss of empathy, compulsivity, and dietary changes
Logopenic Variant PPA (lvPPA)Word-finding pauses and memory lapses
Age-specific10-20 per 100,000 in individuals aged 45-64 years
Gender distributionSlight male predominance (1.5:1) in bvFTD
SurvivalMedian survival 6-11 years from symptom onset
Type ANeuronal intranuclear inclusions (NII) and neuronal cytoplasmic inclusions (NCI); associated with **GRN** mutations
Type BDiffuse NCI without NII; associated with **C9orf72** expansions
Type CNCI predominant; typical of semantic variant PPA
VCP-associatedInclusion body myopathy with Paget disease of bone (IBMPFD) and FTD; **VCP** mutations cause TDP-43 pathology
Pick's Disease3R tau filaments, Pick bodies, focal frontal/temporal atrophy
Argyrophilic Grain Disease (AGD)Argyrophilic grain disease, 4R tau, mild cognitive impairment
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (80)

Purinergic Signaling Polarization Control
Score: 0.71
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
HDAC3-Selective Inhibition for Clock Reset
Score: 0.71
Autophagosome Maturation Checkpoint Control
Score: 0.71
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Lysosomal Enzyme Trafficking Correction
Score: 0.71
Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat
Score: 0.71
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.70
Axonal RNA Transport Reconstitution
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Ocular Immune Privilege Extension
Score: 0.69
Extracellular Matrix Stiffness Modulation
Score: 0.69
Reelin-Mediated Cytoskeletal Stabilization Protocol
Score: 0.69
Cross-Seeding Prevention Strategy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
← Prevpg 2/4Next →

Related Analyses (21)

SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas
neurodegeneration · completed
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived

Related Experiments (22)

Tau ASO Therapy
validation · proposed · Score: 0.40
Epigenetic Clocks in Neurodegeneration — Causal Drivers or P
validation · completed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Presymptomatic GRN Carrier Intervention Timing — Biomarker-G
clinical · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.